A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

Lin Cai(Peking University), Jianzhong Zhang(Chinese Academy of Sciences), Hong Fang(The University of Texas MD Anderson Cancer Center), Wenli Feng, Congjun Jiang(First Affiliated Hospital of Bengbu Medical College), Kun Huang(University of British Columbia), Shan Jiang(China Geological Survey), Weili Pan, Lan-Ying Qin, Lunfei Liu, Xiaojing Kang(Shinshu University), Xinsuo Duan(Affiliated Hospital of Chengde Medical College), Guang‐Ming Han, Tiechi Lei(Peking University), Juan Tao(Union Hospital), Rong Xiao(Tongji University), Rongyi Chen(Peking University), Qianjin Lu(Central South University), Chengxin Li(Chinese PLA General Hospital), Shanshan Li(Peking University), Guoqiang Zhang(Hebei Medical University), Bin Chen(Sichuan University), Chunlei Zhang(Peking University), Yi Zhao(Beijing Tsinghua Chang Gung Hospital), Xiaofang Zhu, Yumei Li(Qingdao University), Jinyan Wang(Ningbo No. 2 Hospital), Juan Su(Ministry of Education), Xiao-Wen Pang(Air Force General Hospital PLA), Litao Zhang(Tianjin University of Traditional Chinese Medicine), Huiping Wang(Chinese National Human Genome Center), Jianbin Yu(Creative Commons), Chunjun Yang(Anhui Medical University), Shoumin Zhang(Zhengzhou University), Hui Xu, Chunxing Xu(The First People's Hospital of Changzhou), Mao Lin(First Affiliated Hospital Zhejiang University), Ruihua Fang(Pacific Northwest National Laboratory), Wei Wang(Guangxi University), Yangfeng Ding(Shanghai Stomatological Hospital)
British Journal of Dermatology
February 15, 2024
Cited by 21


Related Papers